This trial is testing a new drug, ABX196, to see if it is safe and effective in treating hepatocellular carcinoma when used with nivolumab.
- Hepatocellular Carcinoma
1 Primary · 4 Secondary · Reporting Duration: Through study completion, an average of 1 year
1 Treatment Group
1 of 1
48 Total Participants · 1 Treatment Group
Primary Treatment: ABX196 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 13 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this investigation unprecedented in its approach?
"Presently, ABX196 is being trialled at two locations across one nation. The inaugural trial for the drug was conducted in 2019 by Abivax S.A., and involved 48 patients who completed both phases of clinical testing successfully. Since then, no further studies have been concluded." - Anonymous Online Contributor
What is the current participant count of this clinical experiment?
"Affirmative. According to the clinicaltrials.gov website, this investigation is actively recruiting patients who meet their criteria. This study was first published on August 30th 2019 and has since been modified on March 25th 2021. 48 participants need to be enrolled between two medical sites in order for it to progress further." - Anonymous Online Contributor
To what extent has ABX196 been tested in prior research?
"Currently, there is only one active clinical trial researching ABX196 with no Phase 3 trials in effect. Most of the research for this drug is taking place at Houston, Texas though two other sites are also running relevant tests." - Anonymous Online Contributor
Are there any opportunities for volunteers to join this research project?
"According to clinicaltrials.gov, this research is seeking participants at the moment; it was initially advertised on August 30th 2019 and recently revisited on March 25 2021." - Anonymous Online Contributor